The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
New horizons in adjuvants for vaccine development
Open accessAbstract
Adjuvant molecules, particularly toll like receptor (TLR) agonists have been in development for decades, though until now only a natural TLR 4 ligand (mono-phosphoryl lipid A, MPL) has been incorporated into licensed vaccine products, in formulations than enhance and complement the MPL activity. The inclusion of MPL-based formulations into vaccines has been based on enhancing antibody responses to subunit antigens, and has provided important proof-of-concept for enhancing desired immune responses to defined molecular targets. Challenges remain in adjuvant development, particularly for those that stimulated effective T cell responses for both preventative and therapeutic vaccines. The discovery of molecules, many based on RNA, that stimulate innate and adaptive immune responses and have the ability to stimulate potent CD8 T cell responses, has opened the door for development of a new generation of vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Janeway, C. A., & Medzhitov, R. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.083001.084359 · Cited by 8,394
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Toll-Like Receptor Signaling Pathways
Kawasaki, T., & Kawai, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00461 · Cited by 3,233
Immune Signaling by RIG-I-like Receptors
Loo, Y.-M., & Gale, M. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.003 · Cited by 1,875 · cited 1×
“RIG-I and MDA5 function as essential PRRs for the primary recognition of RNA virus infection whereas LGP2 is less-well understood but is thought to regulate RIG-I and MDA5 function [26].”
Self-citationHow dying cells alert the immune system to danger
Kono, H., & Rock, K. L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2215 · Cited by 1,737
TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity
Gack, M. U., Shin, Y. C., Joo, C.-H., Urano, T., Liang, C., Sun, L., Takeuchi, O., Akira, S., Chen, Z., Inoue, S., et al. (2007) · Nature · doi:10.1038/nature05732 · Cited by 1,695
Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., Wheeler, C. M., Koutsky, L. A., Malm, C., Lehtinen, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70101-7 · Cited by 1,579
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
Eisenbarth, S. C., Colegio, O. R., O’Connor, W., Sutterwala, F. S., & Flavell, R. A. (2008) · Nature · doi:10.1038/nature06939 · Cited by 1,542
Kool, M., Soullié, T., van Nimwegen, M., Willart, M. A. M., Muskens, F., Jung, S., Hoogsteden, H. C., Hammad, H., & Lambrecht, B. N. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071087 · Cited by 993
Jiang, W., Swiggard, W. J., Heufler, C., Peng, M., Mirza, A., Steinman, R. M., & Nussenzweig, M. C. (1995) · Nature · doi:10.1038/375151a0 · Cited by 964
Stoute, J. A., Slaoui, M., Heppner, D. G., Momin, P., Kester, K. E., Desmons, P., Wellde, B. T., Garçon, N., Krzych, U., Marchand, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360202 · Cited by 870
Helping the CD8+ T-cell response
Bevan, M. J. (2004) · Nature Reviews Immunology · doi:10.1038/nri1413 · Cited by 797
ER–phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells
Guermonprez, P., Saveanu, L., Kleijmeer, M., Davoust, J., van Endert, P., & Amigorena, S. (2003) · Nature · doi:10.1038/nature01911 · Cited by 753
Pattern recognition receptors and control of adaptive immunity
Palm, N. W., & Medzhitov, R. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00731.x · Cited by 729
Phagosomes are competent organelles for antigen cross-presentation
Houde, M., Bertholet, S., Gagnon, E., Brunet, S., Goyette, G., Laplante, A., Princiotta, M. F., Thibault, P., Sacks, D., & Desjardins, M. (2003) · Nature · doi:10.1038/nature01912 · Cited by 699
Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8
Gorden, K. B., Gorski, K. S., Gibson, S. J., Kedl, R. M., Kieper, W. C., Qiu, X., Tomai, M. A., Alkan, S. S., & Vasilakos, J. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1259 · Cited by 683
Self-citationNanotechnology in vaccine delivery
Peek, L. J., Middaugh, C. R., & Berkland, C. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.017 · Cited by 562
Targeting the innate immune response with improved vaccine adjuvants
Pashine, A., Valiante, N. M., & Ulmer, J. B. (2005) · Nature Medicine · doi:10.1038/nm1210 · Cited by 555
Mahnke, K., Guo, M., Lee, S., Sepulveda, H., Swain, S. L., Nussenzweig, M., & Steinman, R. M. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.151.3.673 · Cited by 544
Bojang, K. A., Milligan, P. J., Pinder, M., Vigneron, L., Alloueche, A., Kester, K. E., Ballou, W. R., Conway, D. J., Reece, W. H., Gothard, P., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06957-4 · Cited by 528
Singh, M., & O'Hagan, D. (1999) · Nature Biotechnology · doi:10.1038/15058 · Cited by 506
Wu, Y., Ellis, R. D., Shaffer, D., Fontes, E., Malkin, E. M., Mahanty, S., Fay, M. P., Narum, D., Rausch, K., Miles, A. P., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002636 · Cited by 449
Brewer, J. M., Conacher, M., Hunter, C. A., Mohrs, M., Brombacher, F., & Alexander, J. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.12.6448 · Cited by 440
Use of defined TLR ligands as adjuvants within human vaccines
Duthie, M. S., Windish, H. P., Fox, C. B., & Reed, S. G. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00978.x · Cited by 437
Self-citationSeubert, A., Monaci, E., Pizza, M., O’Hagan, D. T., & Wack, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.8.5402 · Cited by 430
RIG-I and Other RNA Sensors in Antiviral Immunity
Chow, K. T., Gale, M., & Loo, Y.-M. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053309 · Cited by 429
Self-citationRIG-I in RNA virus recognition
Kell, A. M., & Gale, M. (2015) · Virology · doi:10.1016/j.virol.2015.02.017 · Cited by 428
Self-citationAckerman, A. L., Kyritsis, C., Tampé, R., & Cresswell, P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1735556100 · Cited by 383
Recognition of viruses by innate immunity
Takeuchi, O., & Akira, S. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00562.x · Cited by 342
Immunological concepts of vaccine adjuvant activity
Schijns, V. E. (2000) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00120-5 · Cited by 330
Ligand recognition by antigen-presenting cell C-type lectin receptors
McGreal, E. P., Miller, J. L., & Gordon, S. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.12.001 · Cited by 310
MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines
Ott, G., Barchfeld, G. L., Chernoff, D., Radhakrishnan, R., van Hoogevest, P., & Van Nest, G. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_10 · Cited by 298
Caskey, M., Lefebvre, F., Filali-Mouhim, A., Cameron, M. J., Goulet, J.-P., Haddad, E. K., Breton, G., Trumpfheller, C., Pollak, S., Shimeliovich, I., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20111171 · Cited by 271
Second-generation vaccines against leishmaniasis
COLER, R., & REED, S. (2005) · Trends in Parasitology · doi:10.1016/j.pt.2005.03.006 · Cited by 266
Self-citationThe use of Toll-like receptor 7/8 agonists as vaccine adjuvants
Vasilakos, J. P., & Tomai, M. A. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.811208 · Cited by 254
Self-citationUlanova, M., Tarkowski, A., Hahn-Zoric, M., & Hanson, L. Å. (2001) · Infection and Immunity · doi:10.1128/iai.69.2.1151-1159.2001 · Cited by 239
Aggregates Are the Biologically Active Units of Endotoxin
Mueller, M., Lindner, B., Kusumoto, S., Fukase, K., Schromm, A. B., & Seydel, U. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401231200 · Cited by 236
Vaccine adjuvants as potential cancer immunotherapeutics
Temizoz, B., Kuroda, E., & Ishii, K. J. (2016) · International Immunology · doi:10.1093/intimm/dxw015 · Cited by 227
Liu, H. M., Loo, Y.-M., Horner, S. M., Zornetzer, G. A., Katze, M. G., & Gale, M. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.04.006 · Cited by 207
Self-citationStahl-Hennig, C., Eisenblätter, M., Jasny, E., Rzehak, T., Tenner-Racz, K., Trumpfheller, C., Salazar, A. M., Überla, K., Nieto, K., Kleinschmidt, J., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000373 · Cited by 198
Edwards, D. K., Jasny, E., Yoon, H., Horscroft, N., Schanen, B., Geter, T., Fotin-Mleczek, M., Petsch, B., & Wittman, V. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-016-1111-6 · Cited by 186
Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly
De Donato, S., Granoff, D., Minutello, M., Lecchi, G., Faccini, M., Agnello, M., Senatore, F., Verweij, P., Fritzell, B., & Podda, A. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00138-3 · Cited by 184
Duewell, P., Steger, A., Lohr, H., Bourhis, H., Hoelz, H., Kirchleitner, S. V., Stieg, M. R., Grassmann, S., Kobold, S., Siveke, J. T., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.96 · Cited by 179
Smirnov, D., Schmidt, J. J., Capecchi, J. T., & Wightman, P. D. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.061 · Cited by 174
Marchand, M., Punt, C. J. A., Aamdal, S., Escudier, B., Kruit, W. H. J., Keilholz, U., Håkansson, L., van Baren, N., Humblet, Y., Mulders, P., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00479-3 · Cited by 169
Straus, S. E., Wald, A., Kost, R. G., McKenzie, R., Langenberg, A. G. M., Hohman, P., Lekstrom, J., Cox, E., Nakamura, M., Sekulovich, R., et al. (1997) · The Journal of Infectious Diseases · doi:10.1086/514103 · Cited by 169
Toll or Toll-Free Adjuvant Path Toward the Optimal Vaccine Development
Ishii, K. J., & Akira, S. (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-007-9087-x · Cited by 168
Monophosphoryl Lipid A (MPL) Formulations for the Next Generation of Vaccines
Baldridge, J. R., & Crane, R. T. (1999) · Methods · doi:10.1006/meth.1999.0834 · Cited by 168
Arunachalam, P. S., Charles, T. P., Joag, V., Bollimpelli, V. S., Scott, M. K. D., Wimmers, F., Burton, S. L., Labranche, C. C., Petitdemange, C., Gangadhara, S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0858-8 · Cited by 165
Self-citationThe global impact of vaccines containing aluminium adjuvants
Clements, C. J., & Griffiths, E. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00168-8 · Cited by 164
Harding, C. V., Collins, D. S., Kanagawa, O., & Unanue, E. R. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.9.2860 · Cited by 161
TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours
Conroy, H., Marshall, N. A., & Mills, K. H. G. (2008) · Oncogene · doi:10.1038/sj.onc.1210910 · Cited by 160
Age-related decline in immunity: implications for vaccine responsiveness
Kumar, R., & Burns, E. A. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.4.467 · Cited by 160
Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants
Dowling, D. J. (2018) · ImmunoHorizons · doi:10.4049/immunohorizons.1700063 · Cited by 160
Kasturi, S. P., Rasheed, M. A. U., Havenar‐Daughton, C., Pham, M., Legere, T. H., Sher, Z. J., Kovalenkov, Y. O., Gumber, S., Huang, J. Y., Gottardo, R., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abb1025 · Cited by 155
Self-citationTewari, K., Flynn, B., Boscardin, S., Kastenmueller, K., Salazar, A., Anderson, C., Soundarapandian, V., Ahumada, A., Keler, T., Hoffman, S., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.08.098 · Cited by 153
Chwalek, M., Lalun, N., Bobichon, H., Plé, K., & Voutquenne‐Nazabadioko, L. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2006.05.004 · Cited by 152
Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial
Kyi, C., Roudko, V., Sabado, R. L., Saenger, Y. M., Loging, W., Mandeli, J., Thin, T. H., Lehrer, D., Donovan, M. J., Posner, M. R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1866 · Cited by 149
Ott, G., Barchfeld, G. L., & Nest, G. V. (1995) · Vaccine · doi:10.1016/0264-410x(95)00089-j · Cited by 147
Building an immune system from nine domains
Pålsson‐McDermott, E. M., & O'Neill, L. A. J. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351437 · Cited by 147
Lee, H.-H., Hoeman, C. M., Hardaway, J. C., Guloglu, F. B., Ellis, J. S., JAIN, R. K., Divekar, R. D., Tartar, D. M., Haymaker, C., & Zaghouani, H. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071371 · Cited by 140
Structural and Immunological Characterization of the Vaccine Adjuvant QS-21
Kensil, C. R., Wu, J., & Soltysik, S. (1995) · Pharmaceutical biotechnology · doi:10.1007/978-1-4615-1823-5_22 · Cited by 139
Rimmelzwaan, G. F., Nieuwkoop, N., Brandenburg, A., Sutter, G., Beyer, W. E., Maher, D., Bates, J., & Osterhaus, A. D. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00310-8 · Cited by 136
Miranda‐Verástegui, C., Llanos‐Cuentas, A., Arevalo, I., Ward, B. J., & Matlashewski, G. (2005) · Clinical Infectious Diseases · doi:10.1086/429238 · Cited by 129
Bayry, J., Tchilian, E. Z., Davies, M. N., Forbes, E. K., Draper, S. J., Kaveri, S. V., Hill, A. V. S., Kazatchkine, M. D., Beverley, P. C. L., Flower, D. R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803453105 · Cited by 126
Wu, H., & Russell, M. W. (1998) · Vaccine · doi:10.1016/s0264-410x(97)00168-0 · Cited by 122
The use of oil adjuvants in therapeutic vaccines
Aucouturier, J., Ascarateil, S., & Dupuis, L. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.116 · Cited by 120
The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview
Stockfleth, E., Trefzer, U., Garcia-Bartels, C., Wegner, T., Schmook, T., & Sterry, W. (2003) · British Journal of Dermatology · doi:10.1046/j.0366-077x.2003.05626.x · Cited by 119
TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth
Dowling, D. J., van Haren, S. D., Scheid, A., Bergelson, I., Kim, D., Mancuso, C. J., Foppen, W., Ozonoff, A., Fresh, L., Theriot, T. B., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91020 · Cited by 111
Self-citationUridine Composition of the Poly-U/UC Tract of HCV RNA Defines Non-Self Recognition by RIG-I
Schnell, G., Loo, Y., Marcotrigiano, J., & Gale, M. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002839 · Cited by 109
Self-citationEnnis, F. A., Cruz, J., Jameson, J., Klein, M. H., Burt, D. S., & Thipphawong, J. (1999) · Virology · doi:10.1006/viro.1999.9765 · Cited by 109
Okada, H., Butterfield, L. H., Hamilton, R. L., Hoji, A., Sakaki, M., Ahn, B. J., Kohanbash, G., Drappatz, J., Engh, J. A., Amankulor, N., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1790 · Cited by 108
Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix???]
Keam, S. J., & Harper, D. M. (2008) · Drugs · doi:10.2165/00003495-200868030-00007 · Cited by 107
Vaccinology at the beginning of the 21st century
Wack, A., & Rappuoli, R. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.05.005 · Cited by 104
Heineman, T. C., Clements-Mann, M. L., Poland, G. A., Jacobson, R. M., Izu, A. E., Sakamoto, D., Eiden, J., Nest, G. A. V., & Hsu, H. H. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00088-2 · Cited by 103
Elion, D. L., & Cook, R. S. (2018) · Oncotarget · doi:10.18632/oncotarget.25626 · Cited by 101
Virus-sized vaccine delivery systems
Scheerlinck, J. Y., & Greenwood, D. L. V. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.06.016 · Cited by 99
Ryan, E. J., McNeela, E. A., Murphy, G. A., Stewart, H., O’Hagan, D. T., Pizza, M., Rappuoli, R., & Mills, K. H. G. (1999) · Infection and Immunity · doi:10.1128/iai.67.12.6270-6280.1999 · Cited by 98
Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children
Bojang, K., Olodude, F., Pinder, M., Ofori‐Anyinam, O., Vigneron, L., Fitzpatrick, S., Njie, F., Kassanga, A., Leach, A. J., Milman, J., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.03.019 · Cited by 95
Edelman, R. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.2.167 · Cited by 92
Van Hoeven, N., Fox, C. B., Granger, B., Evers, T., Joshi, S. W., Nana, G. I., Evans, S. C., Lin, S., Liang, H., Liang, L., et al. (2017) · Scientific Reports · doi:10.1038/srep46426 · Cited by 87
Self-citationKulkarni, R. R., Rasheed, M. A. U., Bhaumik, S. K., Ranjan, P., Cao, W., Davis, C. W., Marisetti, K., Thomas, S., Gangappa, S., Sambhara, S. R., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02273-14 · Cited by 83
Synthetic TLR4-active Glycolipids as Vaccine Adjuvants and Stand-alone Immunotherapeutics
Johnson, D. A. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608783378882 · Cited by 81
TLR4 agonists as immunomodulatory agents
Alderson, M. R., McGowan, P., Baldridge, J. R., & Probst, P. (2006) · Journal of Endotoxin Research · doi:10.1179/096805106x118753 · Cited by 80
Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway
Pattabhi, S., Wilkins, C. R., Dong, R., Knoll, M. L., Posakony, J., Kaiser, S. M., Mire, C. E., Wang, M. L., Ireton, R. C., Geisbert, T. W., et al. (2015) · Journal of Virology · doi:10.1128/jvi.02202-15 · Cited by 80
Self-citationRIG-I-like receptors direct inflammatory macrophage polarization against West Nile virus infection
Stone, A. E. L., Green, R. R., Wilkins, C. R., Hemann, E. A., & Gale, M. (2019) · Nature Communications · doi:10.1038/s41467-019-11250-5 · Cited by 71
Self-citationPichyangkul, S., Gettayacamin, M., MILLER, R., Lyon, J. A., Angov, E., Tongtawe, P., RUBLE, D., HEPPNERJR, D., Kester, K. E., & Ballou, W. R. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.07.023 · Cited by 69
Tuberculosis vaccine development
Doherty, T. M., & Andersen, P. L. (2002) · Current Opinion in Pulmonary Medicine · doi:10.1097/00063198-200205000-00006 · Cited by 69
Nod‐like receptors in innate immunity and inflammatory diseases
Carneiro, L. A. M., Travassos, L. H., & Girardin, S. E. (2007) · Annals of Medicine · doi:10.1080/07853890701576172 · Cited by 68
Sprokholt, J. K., Kaptein, T. M., van Hamme, J. L., Overmars, R. J., Gringhuis, S. I., & Geijtenbeek, T. B. H. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1602121 · Cited by 68
Bharucha, T., Ming, D. K. Y., & Breuer, J. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1317410 · Cited by 67
The development and use of vaccine adjuvants
Edelman, R. (2002) · Molecular Biotechnology · doi:10.1385/mb:21:2:129 · Cited by 66
The potential of 1018 ISS adjuvant in hepatitis B vaccines
Eng, N. F., Bhardwaj, N., Mulligan, R., & Díaz‐Mitoma, F. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.24715 · Cited by 65
Influenza virosomes as an efficient system for adjuvanted vaccine delivery
Glück, R., Moser, C., & Metcalfe, I. C. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.7.1139 · Cited by 63
Immunostimulatory DNA as a vaccine adjuvant
Higgins, D., Marshall, J. D., Traquina, P., Nest, G. V., & Livingston, B. D. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.747 · Cited by 62
Fox, C. B., Orr, M. T., Hoeven, N. V., Parker, S. C., Mikasa, T. J. T., Phan, T., Beebe, E. A., Nana, G. I., Joshi, S. W., Tomai, M. A., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.011 · Cited by 60
Self-citationRegulation of Antiviral Innate Immune Responses by RIG-I Family of RNA Helicases
Onomoto, K., Yoneyama, M., & Fujita, T. (2007) · Springer eBooks · doi:10.1007/978-3-540-71329-6_10 · Cited by 59
Development of a leishmaniasis vaccine: the importance of MPL
Reed, S. G., Coler, R. N., & Campos‐Neto, A. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.2.239 · Cited by 59
Self-citationSprokholt, J. K., Kaptein, T. M., van Hamme, J. L., Overmars, R. J., Gringhuis, S. I., & Geijtenbeek, T. B. H. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006738 · Cited by 59
McCormack, S., Tilzey, A., Carmichael, A. J., Gotch, F., Kepple, J., Newberry, A. M., Jones, G. J., Lister, S. G., Beddows, S. A., CHEINGSONG-POPOV, R., et al. (2000) · Vaccine · doi:10.1016/s0264-410x(99)00388-6 · Cited by 58
Tuberculosis vaccine development; from mouse to man
Reed, S. G., & Lobet, Y. (2005) · Microbes and Infection · doi:10.1016/j.micinf.2005.03.011 · Cited by 54
Self-citationActivation of Dendritic Cells by the Novel Toll-Like Receptor 3 Agonist RGC100
Naumann, K., Wehner, R., Schwarze, A., Petzold, C., Schmitz, M., & Rohayem, J. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/283649 · Cited by 54
Byars, N. E., ALLISON, A. C., Harmon, M. W., & Kendal, A. P. (1990) · Vaccine · doi:10.1016/0264-410x(90)90177-n · Cited by 52
Radošević, K., Rodrı́guez, A., Mintardjo, R., Tax, D., Bengtsson, K. L., Thompson, C., Zambon, M. C. F. A., Weverling, G. J., UytdeHaag, F. G. C. M., & Goudsmit, J. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.04.071 · Cited by 51
Probst, P., Grigg, J. B., Wang, M., Muñoz, E. J., Loo, Y., Ireton, R. C., Gale, M., Iadonato, S. P., & Bedard, K. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.01.053 · Cited by 42
Self-citationBarackman, J. D., Ott, G. S., Pine, S. O., & O’Hagan, D. T. (2001) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.8.3.652-657.2001 · Cited by 39
Abhyankar, M. M., Orr, M. T., Lin, S. X., Suraju, M. O., Simpson, A., Blust, M., Pham, T., Guderian, J. A., Tomai, M. A., Elvecrog, J., et al. (2018) · npj Vaccines · doi:10.1038/s41541-018-0060-x · Cited by 39
Self-citationSambhara, S. R., Kurichh, A., Miranda, R., James, O., Underdown, B. J., Klein, M. C. A., Tartaglia, J., & Burt, D. S. (2001) · Cellular Immunology · doi:10.1006/cimm.2001.1799 · Cited by 36
Adjuvant formulations and their mode of action.
ALLISON, A. C., & Byars, N. E. (1990) · PubMed · Cited by 31
A Purified Saponin Acts as an Adjuvant for a T-Independent Antigen
White, A. C., Cloutier, P. A., & Coughlin, R. T. (1991) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-6000-1_22 · Cited by 29
Audibert, F., Parant, M., Damais, C., Lefrancier, P., Derrien, M., Choay, J., & CHEDID, L. A. (1980) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(80)91442-4 · Cited by 24
Vaccines and the cold chain: is it too hot… or too cold?
Burgess, M. A., & McIntyre, P. B. (1999) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb123527.x · Cited by 21
O’Donovan, D. H., Mao, Y., & Mele, D. A. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190620103105 · Cited by 19
Cited by
A DNA nanodevice-based vaccine for cancer immunotherapy
Liu, S., Jiang, Q., Zhao, X., Zhao, R., Wang, Y., Wang, Y., Liu, J., Shang, Y., Zhao, S., Wu, T., et al. (2021) · Nature Materials · doi:10.1038/s41563-020-0793-6 · Cited by 548
Oyewumi, M. O., Kumar, A., & Cui, Z. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.89 · Cited by 547
Thi, T. T. H., Suys, E. J. A., Lee, J. S., Nguyen, D. H., Park, K. D., & Truong, N. P. (2021) · Vaccines · doi:10.3390/vaccines9040359 · Cited by 525
Use of defined TLR ligands as adjuvants within human vaccines
Duthie, M. S., Windish, H. P., Fox, C. B., & Reed, S. G. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00978.x · Cited by 437
Self-citationRecent Advances of Vaccine Adjuvants for Infectious Diseases
Lee, S., & Nguyen, M. T. (2015) · Immune Network · doi:10.4110/in.2015.15.2.51 · Cited by 385
Metadata
- Authors
- Reed, S. G., Tomai, M., & Gale, M. J.
- Venue
- Current Opinion in Immunology
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 65
- Pages
- 97-101
- ISSN
- 0952-7915 (ISSN-L)
- OpenAlex
- W3091948925
- Cited by
- 554
- References
- 113
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.